Antibody Therapeutic / ADC Target Proteins

2973 products

Antibody drug conjugate in blue with four drug compounds linked to IgG immunoglobulin

Antibody-Drug Conjugate is a complex that combines an antibody and a drug for the targeted treatment of cancer and other diseases. ADCs combine monoclonal antibodies, drugs, and linkers to achieve selective killing of specific targets.

The composition of ADC includes three main components: 1. Monoclonal antibody: select monoclonal antibodies with high affinity and specificity, which can bind to specific antigens on the surface of cancer cells. The role of the antibody is to recognize and localize cancer cells and to prompt the binding of the ADC to the cancer cells. 2. Linker: A linker is a chemical structure used to link an antibody to a drug. It can provide stable binding and release the drug at the right time. 3. Cytotoxic drugs: Cytotoxic drugs are the drug components of ADC, which can kill or inhibit the growth and proliferation of cancer cells. These drugs are usually chemotherapeutic drugs or other molecules with cytotoxic activity.

The working principle of ADC is to guide drugs to cancer cells through the specific recognition of antibodies. Once the ADC binds to cancer cells, the drug is released and exerts cytotoxic effects, directly killing cancer cells or blocking their growth signaling pathways. Compared with traditional chemotherapy drugs, ADC can act on cancer cells more precisely and reduce damage to normal cells.

ADCs have many potential advantages, including increased local concentration of drugs, improved therapeutic efficacy, reduced drug side effects, and increased patient survival. It has shown potential in several cancer types, such as breast cancer, lymphoma and lung cancer, among others. However, ADCs also face some challenges, including issues such as drug stability, drug release rate, and immunogenicity. Researchers are working to improve the design and optimization of ADCs to improve their therapeutic efficacy and safety.

Overall, ADC is an innovative drug therapy strategy that achieves precise targeted therapy against cancer cells by combining the properties of antibodies and drugs. With the continuous development of technology and the deepening of research, ADC is expected to become an important breakthrough in the field of cancer treatment.

Beta LifeScience offers a wide range of high-quality target proteins that are crucial for the development of ADCs. Our portfolio includes MMPs, Cathepsin, and uPA, which are particularly valuable for the development of cleavable linkers, enabling controlled drug release. By collaborating with Beta LifeScience, you can access the necessary tools and resources to advance your ADC research and drug development endeavors.


    2973 products